Aberdeen Group plc Sells 234,399 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT
Aberdeen Group plc reduced its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 22.7% in the third quarter of 2025, selling 234,399 shares and retaining 796,802 shares valued at $11.346 million. This reduction leaves Aberdeen Group plc owning approximately 1.16% of the company. Despite this sale, analysts remain largely bullish on EYPT, with an average rating of "Buy" and an average price target of $29.25, though one analyst has a "sell" rating.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 4.4% - Time to Sell?
Eyepoint Pharmaceuticals (NASDAQ:EYPT) saw its shares drop 4.4% during mid-day trading with increased volume. Despite the dip, analyst sentiment remains largely positive, with a consensus "Buy" rating and an average price target of $29.25, supported by recent upgrades from RBC, TD Cowen, and Cantor Fitzgerald. However, one insider recently sold a significant number of shares, while institutional ownership is high.
EyePoint appoints Michael Campbell as chief commercial officer
EyePoint, Inc. has appointed Michael Campbell as Chief Commercial Officer to lead the commercial strategy for its investigational treatment, DURAVYU, currently in Phase 3 development. Campbell brings over 30 years of ophthalmology commercial experience, including a key role in the launch of Lucentis. His appointment comes as EyePoint anticipates topline data from its Phase 3 program in wet AMD in mid-2026.
Is EyePoint’s New Commercial Chief the Missing Piece in the DURAVYU Story for EYPT Investors?
EyePoint, Inc. has appointed Michael Campbell as Chief Commercial Officer to spearhead the commercial strategy for DURAVYU, its Phase 3 candidate for wet age-related macular degeneration and diabetic macular edema. Campbell's extensive experience in ophthalmology product launches is expected to be a significant asset, though EyePoint still faces challenges with high cash burn and dependence on external capital to fund DURAVYU's development and commercialization. The success of DURAVYU remains central to EyePoint's investment narrative, with diverse analyst forecasts highlighting both potential upside and considerable risks for investors.
EyePoint Appoints Michael Campbell as Chief Commercial Officer
EyePoint Pharmaceuticals, Inc. has announced the appointment of Michael Campbell as its new Chief Commercial Officer. Campbell brings over 30 years of commercial leadership experience in retinal disease, with a strong track record of successful product launches for prominent ophthalmology franchises like Lucentis® and Xiidra®. He will be responsible for EyePoint's commercial strategy and launch readiness for DURAVYU™, an investigational sustained-release treatment for wet age-related macular degeneration and diabetic macular edema, which is currently in Phase 3 development.
Eyepoint Pharmaceuticals appoints Campbell to boost product launches
Eyepoint Pharmaceuticals has appointed Michael Campbell as Chief Commercial Officer (CCO) to enhance its product offerings and market presence. Campbell brings over 30 years of commercial leadership experience and a strong background in successful product launches. His role will be crucial in the company's aim to deliver the first sustained-release TKI to patients.
EyePoint Appoints Michael Campbell as Chief Commercial Officer
EyePoint Pharmaceuticals, Inc. has appointed Michael Campbell as its Chief Commercial Officer. Campbell brings over 30 years of experience in retinal disease commercial leadership, including successful product launches for Lucentis® and Xiidra®. He will lead EyePoint's commercial strategy and launch readiness for DURAVYU™, an investigational treatment for wet AMD and DME currently in Phase 3 development.
EyePoint Appoints Michael Campbell as Chief Commercial Officer
EyePoint, Inc. has appointed Michael Campbell as its Chief Commercial Officer, a seasoned executive with over 30 years of leadership in retinal disease. Campbell will oversee the commercial strategy and launch readiness for DURAVYU, EyePoint's leading product candidate in Phase 3 development for wet AMD and DME. His extensive experience, including successful launches of prominent ophthalmology franchises like Lucentis and Xiidra, is expected to be instrumental in positioning DURAVYU for market success.
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?
EyePoint (EYPT) shares increased by 15.2% due to positive developments with its lead candidate, Duravyu, particularly encouraging clinical progress in late-stage trials. While the company is projected to report a quarterly loss and decreased revenues, investor confidence is boosted by reduced regulatory uncertainty and the drug's potential in retinal diseases. The stock currently holds a Zacks Rank #3 (Hold), and its future performance will depend on sustained trends in earnings estimate revisions.
EyePoint (EYPT) Surges 15.2%: Is This an Indication of Further Gains?
EyePoint (EYPT) shares surged 15.2% in the last trading session, closing at $14.91, driven by positive developments with its lead candidate, Duravyu. Despite this price surge and investor enthusiasm around clinical progress, the company is expected to post a quarterly loss and a significant revenue decline. Analysts suggest that without a trend in earnings estimate revisions, further sustained gains might be limited, as the stock currently holds a Zacks Rank #3 (Hold).
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint, Inc. announced the granting of non-statutory stock options to six new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options cover an aggregate of 143,000 shares of EyePoint common stock, with an exercise price of $12.94 per share. The awards vest over four years, subject to continued employment, aiming to attract and retain talent in their mission to develop therapeutics for serious retinal diseases.
Guggenheim reiterates EyePoint stock rating on rival trial data
Guggenheim maintained a Buy rating and $68.00 price target on EyePoint Inc. after positive Phase III trial results from a competitor, Ocular Therapeutix, de-risked the entire TKI class of treatments for wet age-related macular degeneration. EyePoint is conducting its own non-inferiority trials for its TKI insert, Duravyu, with data expected mid-2026. Despite a challenging year for EyePoint's stock, Guggenheim expects its valuation gap with Ocular Therapeutix to narrow and considers it a top pick due to its robust clinical strategy, financial flexibility, and potential to be first to market.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) announced inducement grants of non-statutory stock options to six new employees, totaling 143,000 shares of common stock. These grants were made outside the Company’s 2023 Long-Term Incentive Plan, in accordance with NASDAQ Listing Rule 5635(c)(4), to incentivize their employment. The options have an exercise price of $12.94 per share, a ten-year term, and vest over four years.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals announced inducement grants of non-statutory stock options to six new employees, totaling 143,000 shares of common stock. These grants, with an exercise price of $12.94 per share, were made in accordance with NASDAQ Listing Rule 5635(c)(4) and are designed to incentivize new hires. The options vest over four years, aligning with the company's commitment to developing therapeutics for serious retinal diseases.
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Brokerages
Eyepoint Pharmaceuticals (NASDAQ:EYPT) has received a consensus "Buy" rating from seven brokerages, with an average 12-month price target of $29.25. Insider Ramiro Ribeiro recently sold shares worth over $727,502, while institutional investors hold 99.41% of the company's stock. The company, focused on therapies for ocular diseases with a market cap of $1.07 billion, currently trades around $12.94.
EyePoint Pharmaceuticals Teases Mid-2026 DURAVYU Wet AMD Data, Starts Phase III DME Program
EyePoint Pharmaceuticals announced that it expects to report mid-2026 data from its LUGANO Phase III wet AMD trial, with the LUCIA trial following shortly after. The company also initiated Phase III programs (COMO and CAPRI) for diabetic macular edema (DME), expecting first patient dosing this quarter and data by late 2027. DURAVYU, a vorolanib intravitreal insert, aims for long-term dosing and non-inferiority to aflibercept, with EyePoint planning a solo U.S. commercial launch and having sufficient cash runway into Q4 2027.
EyePoint Pharmaceuticals Teases Mid-2026 DURAVYU Wet AMD Data, Starts Phase III DME Program
EyePoint Pharmaceuticals announced that data from its Phase III wet AMD trial, LUGANO, is expected mid-2026, with the primary goal of non-inferiority to aflibercept. The company also initiated a Phase III program for diabetic macular edema (DME) with two trials, COMO and CAPRI, expecting initial patient dosing this quarter and data by the end of 2027. EyePoint plans a solo U.S. commercial launch for DURAVYU, supported by a $300 million cash runway extending into Q4 2027.
RBC Capital reiterates Outperform rating on EyePoint stock amid recent decline By Investing.com
RBC Capital has reaffirmed its Outperform rating and set a $39.00 price target for EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT), citing confidence in the company's long-acting tyrosine kinase inhibitors (TKIs). Despite a recent 30% year-to-date decline in EyePoint's shares, the firm projects significant upside potential based on promising Phase I/II data, strategic decisions, and manufacturing progress, even as the company's financial health score is currently considered "WEAK" by InvestingPro. Mizuho also reiterated an Outperform rating with a $33.00 price target, highlighting the progress of EyePoint's Phase 3 clinical trials for DURAVYU, with data expected by mid-2026.
RBC Capital reiterates Outperform rating on EyePoint stock amid recent decline
RBC Capital has reaffirmed its Outperform rating and a $39.00 price target for EyePoint Pharmaceuticals Inc. despite a recent 30% year-to-date decline in its stock. The firm's confidence stems from promising Phase I/II data for TKIs in wet age-related macular degeneration, strategic company decisions, and a high success rate for its non-inferiority study approach. This positive outlook stands even with competitor trial results looming and EyePoint currently trading above its InvestingPro Fair Value.
RBC Capital reiterates Outperform rating on EyePoint stock amid recent decline
RBC Capital has reaffirmed an Outperform rating and a $39.00 price target for EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT), maintaining confidence in its long-acting tyrosine kinase inhibitors despite a 30% year-to-date share decline. The firm's conviction is supported by positive Phase I/II data, a high success rate for non-inferiority studies, and strategic company decisions. This reiteration comes as EyePoint's financial health is labeled "WEAK" by InvestingPro, though it holds more cash than debt.
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
EyePoint, Inc. announced that its Executive Vice President and CFO, George O. Elston, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. The company is focused on developing therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU, currently in Phase 3 trials for wet age-related macular degeneration and diabetic macular edema. A webcast of the presentation will be available on EyePoint's investor relations website.
EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
EyePoint Pharmaceuticals, Inc. announced that its Executive Vice President and Chief Financial Officer, George O. Elston, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. This event is scheduled for Thursday, February 12, 2026, at 11:00 am ET. The company is actively developing DURAVYU™, a sustained delivery treatment for serious retinal diseases, which is currently undergoing Phase 3 pivotal trials for wet age-related macular degeneration and diabetic macular edema.
EyePoint, Inc.'s (NASDAQ:EYPT) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
EyePoint, Inc.'s stock experienced a significant 27% retreat over the last 30 days, despite a 68% gain over the past year. The company's price-to-sales (P/S) ratio of 25x is considerably higher than the industry average, which is attributed to strong future revenue growth forecasts of 71% annually over the next three years, compared to the industry's 36%. While current revenue growth has been negative, analysts expect a substantial recovery, justifying the elevated P/S ratio in investors' eyes.
Mizuho reiterates Outperform rating on EyePoint stock amid share weakness By Investing.com
Mizuho has reiterated an Outperform rating and a $33.00 price target for EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) despite recent stock weakness, noting that the decline occurred "on no change in fundamentals." The firm maintains confidence in EyePoint's Duravyu, a TKI-based maintenance therapy for wet AMD, with Phase 3 study results expected by mid-year. Mizuho views the stock as a "top 2026 pick" due to its compelling valuation.
Mizuho reiterates Outperform rating on EyePoint stock amid share weakness
Mizuho has reiterated an Outperform rating and $33.00 price target for EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) despite a 24% year-to-date share decline, emphasizing no change in fundamentals and strong valuation. The firm remains confident in EyePoint's Duravyu, with Phase 3 study results expected by mid-2026, and recognizes the stock as a top 2026 pick. This comes as EyePoint also recently changed its corporate name to EyePoint, Inc. and is progressing with its pivotal clinical trials.
How Eyepoint Pharmaceuticals Inc. (EYPT) Affects Rotational Strategy Timing
Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT) is facing weak near and mid-term sentiment, although it has a strong long-term outlook. AI models have generated three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. These strategies aim to optimize position sizing and minimize drawdown risk.
Federated Hermes Inc. Trims Holdings in Eyepoint Pharmaceuticals, Inc. $EYPT
Federated Hermes Inc. has reduced its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 4.0% in Q3, selling over 183,000 shares but still owning 4.4 million shares valued at about $62.9 million. This comes as an insider sold shares and Eyepoint reported disappointing Q3 earnings, missing both EPS and revenue estimates, alongside steep negative margins. Despite these challenges, Wall Street analysts maintain a "Buy" consensus rating with an average target price of $29.25, and some firms have even raised their price targets.
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and EyePoint Pharmaceuticals (EYPT)
Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on EyePoint Pharmaceuticals (EYPT) with a price target of $33.00, indicating optimism in the healthcare sector. EyePoint Pharmaceuticals currently has a Strong Buy consensus, with an average price target of $31.50 suggesting a significant upside. The article also mentions bullish sentiments from two analysts regarding CVRx (CVRX).
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 5.3% - Here's What Happened
Eyepoint Pharmaceuticals (NASDAQ:EYPT) saw its shares drop by 5.3% on Friday, trading as low as $15.23 with significantly lower than average volume. Despite the recent dip, analysts generally maintain a "Buy" rating for the stock with an average price target of $29.25, though the company missed its recent quarterly EPS and revenue estimates, and an insider sold shares in early January.
(EYPT) and the Role of Price-Sensitive Allocations
This article analyzes Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT), noting weak near and mid-term sentiment despite a positive long-term outlook. It highlights resistance testing, a significant risk-reward short setup, and provides three AI-generated trading strategies for different risk profiles. The strategies include position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
EyePoint, Inc. Grants Stock Options to New Employees as Inducement Awards
EyePoint, Inc. has granted non-statutory stock options for 13,900 shares to three new employees as inducement awards, effective January 15, 2026, with an exercise price of $15.84 per share and a four-year vesting period. This action aligns with NASDAQ Listing Rule 5635(c)(4) to attract talent for its focus on developing treatments for serious retinal diseases, including its lead product candidate DURAVYU™ in Phase 3 trials. The company, headquartered in Watertown, Massachusetts, emphasizes its history of innovation in retinal therapies.
EyePoint offers stock options to three new hires for 13,900 shares
EyePoint (Nasdaq: EYPT) granted non-statutory inducement stock options to three new employees to purchase a total of 13,900 shares of common stock. These options were issued on January 15, 2026, with an exercise price of $15.84 per share and a 10-year term, vesting over four years. This move is consistent with NASDAQ Listing Rule 5635(c)(4) and is considered a routine HR-related disclosure.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint Pharmaceuticals, Inc. announced grants of non-statutory stock options to three new employees as inducement awards, in line with NASDAQ Listing Rule 5635(c)(4). These options cover up to 13,900 shares of common stock, granted on January 15, 2026, with an exercise price of $15.84 per share and a four-year vesting schedule. The company continues to develop and commercialize therapeutics for serious retinal diseases, with lead candidate DURAVYU™.
EyePoint Pharmaceuticals (EYPT) Valuation Check After DURAVYU Phase 3 And NDA Progress
EyePoint Pharmaceuticals is back in focus following a corporate update on DURAVYU's Phase 3 trials and NDA preparations, leading to volatile short-term share price movements but strong longer-term momentum. Despite a narrative valuation suggesting the stock is 55% undervalued, an alternative view highlights a rich sales multiple compared to peers. The company's future valuation heavily relies on DURAVYU clearing late-stage hurdles and effective management of high operating costs.
Responsive Playbooks and the EYPT Inflection
This article analyzes Eyepoint Pharmaceuticals Inc. (NASDAQ: EYPT), noting weak near-term sentiment but strong long-term potential with an exceptional 54.8:1 risk-reward setup. It outlines various AI-generated trading strategies, including long, breakout, and short positions, tailored to different risk profiles and holding periods. The analysis highlights divergent sentiment across time horizons, suggesting choppy conditions, and provides multi-timeframe signal analysis for support and resistance levels.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 4.6% - Here's Why
Eyepoint Pharmaceuticals (NASDAQ:EYPT) stock fell 4.6% on Friday, trading at $16.29 with significantly lower volume. This drop occurred despite a "Buy" consensus rating and a $29.25 price target from analysts, including RBC's raised target of $39. The decline follows the company missing its Q3 earnings and revenue estimates, reporting ($0.85) EPS and $0.97 million in revenue against expectations of ($0.77) and $3.33 million, respectively.
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
EyePoint Pharmaceuticals, Inc. provided a corporate update and highlighted anticipated pivotal milestones for 2026, primarily focusing on its lead product candidate, DURAVYU (vorolanib intravitreal insert). The company is advancing Phase 3 programs for DURAVYU in wet AMD and DME, with topline data for wet AMD expected in mid-2026 and first patient dosing for the DME program in Q1 2026. EyePoint also reported strong financial positioning with $300 million in cash and investments as of December 31, 2025, providing a cash runway into Q4 2027.
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
EyePoint Pharmaceuticals provided a corporate update, highlighting its progress with DURAVYU in wet AMD and DME. The company is on track for Phase 3 wet AMD data readout by mid-2026 and expects to dose the first patient in its Phase 3 DME program in Q1 2026. EyePoint also reported strong financial standing with $300 million in cash and investments, extending its runway into Q4 2027.
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
EyePoint Pharmaceuticals provided a corporate update and outlined key pivotal milestones for 2026, focusing on its lead product candidate, DURAVYU™ (vorolanib intravitreal insert). The company is advancing Phase 3 programs for DURAVYU in wet AMD and DME, with topline data for wet AMD expected in mid-2026 and first patient dosing for DME in Q1 2026. EyePoint also reported a strong financial position with cash runway into Q4 2027, funding key milestones.
Mizuho reiterates Outperform rating on EyePoint stock with $33 target
Mizuho has reiterated an Outperform rating and $33.00 price target for EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) following a corporate update outlining key milestones for 2026. The company is on track to report top-line Phase 3 data for Duravyu, its lead asset for wet age-related macular degeneration (wAMD), in mid-2026 and will dose the first patient in its Phase 3 program for diabetic macular edema (DME) in Q1 2026. EyePoint also reported strong financials with $300 million in cash and investments and a cash runway into Q4 2027, although analysts anticipate a 27% revenue decline for fiscal year 2025.
RBC Capital reiterates Outperform rating on EyePoint stock at $39 target
RBC Capital has reaffirmed its Outperform rating and $39 price target for EyePoint Pharmaceuticals Inc., citing confidence in the company's pivotal wAMD and DME programs which remain on track. The firm highlights EyePoint's strong cash position relative to debt and high conviction in favorable trial outcomes for wAMD, given historical success rates and prior results. Despite a recent stock decline, analysts maintain a strong consensus recommendation, and the company has shown impressive year-over-year returns.
EyePoint’s Phase 3 trials for DURAVYU in wet AMD on track for mid-2026 data
EyePoint Pharmaceuticals, Inc. announced that its Phase 3 clinical trials for DURAVYU in wet AMD are progressing, with data readouts expected to begin in mid-2026. The company has completed enrollment for two Phase 3 wet AMD trials and expects to start dosing for its diabetic macular edema (DME) program in Q1 2026. Despite recent stock volatility and not yet being profitable, EyePoint holds more cash than debt and analysts remain optimistic about its potential.
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
EyePoint, Inc. (Nasdaq: EYPT) has provided a corporate update and outlined its pivotal milestones for 2026, focusing on its lead product candidate, DURAVYU™ (vorolanib intravitreal insert). The company anticipates topline data from its Phase 3 wet AMD program beginning in mid-2026 and expects to dose the first patient in its Phase 3 DME program in Q1 2026. This sustained-release TKI aims to address significant unmet needs in both wet AMD and DME, which are multi-billion-dollar retinal disease markets.
Is EyePoint Pharmaceuticals the Next Sleeper Stock Legend or Just Overhyped Noise?
EyePoint Pharmaceuticals (EYPT) is gaining buzz as a small-cap biotech focused on ophthalmology, but investors question if it's a true game-changer or overhyped. The article delves into the company's scientific approach to eye disease treatment, its pipeline and partnerships, and its volatile stock performance. It concludes that EYPT offers high potential upside for risk-tolerant, informed investors, but is not suitable for those seeking stable returns.
Is EyePoint Pharmaceuticals the Next Sleeper Stock Legend or Just Overhyped Noise?
EyePoint Pharmaceuticals (EYPT) is gaining buzz as a small-cap biotech focused on eye disease drug delivery. While it offers potential for high returns due to its specialized pipeline and partnerships, it also presents significant volatility and risk, characteristic of clinical-stage biotech investments. Investors should approach EYPT as a speculative bet, requiring close monitoring of clinical updates and a high tolerance for risk, rather than a guaranteed "buy and forget" stock.
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts
Eyepoint Pharmaceuticals (NASDAQ:EYPT) has received an average "Buy" rating from analysts, with a consensus one-year price target of $30.00. Despite recent upgrades and increased price targets from several firms, the company faces fundamental challenges including missed quarterly earnings and revenue estimates, negative margins, and a projected negative EPS for the current fiscal year. Institutional investors have significantly increased their stakes in the biopharmaceutical company.
127,489 Shares in Eyepoint Pharmaceuticals, Inc. $EYPT Purchased by Corient Private Wealth LLC
Corient Private Wealth LLC acquired a new stake of 127,489 shares, valued at approximately $1.2 million, in Eyepoint Pharmaceuticals (NASDAQ:EYPT) during the second quarter, representing 0.18% of the company. Despite weak Q2 earnings that missed estimates, analysts maintain a "Buy" consensus rating with an average price target of $30, though the stock's 12-month performance shows a wide range with recent trading around $18.25. Institutional investors and hedge funds collectively own 99.41% of Eyepoint Pharmaceuticals.
Why EyePoint (EYPT) Is Up 9.6% After Upbeat Earnings Revisions And Momentum Signals - And What's Next
EyePoint Pharmaceuticals (EYPT) has experienced a 9.6% stock increase following upward revisions in analyst earnings estimates and a strong Momentum Style Score of A from Zacks. This improvement in financial outlook and momentum signals for the clinical-stage eye-disease specialist is largely driven by progress in its DURAVYU late-stage trial. While the positive sentiment is growing, investors are cautioned about the company's reliance on a single lead asset and the potential for a wide range of fair value estimates, highlighting both significant upside potential and inherent risks.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 6.2% - Time to Sell?
Eyepoint Pharmaceuticals (NASDAQ:EYPT) saw its stock price drop 6.2% on Tuesday, with trading volume significantly below its daily average. Despite weak fundamentals, analyst sentiment remains largely positive with a "Buy" consensus rating and an average price target of $30.00. Institutional investors have been actively adjusting their stakes in the company.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Rating Increased to Strong-Buy at TD Cowen
TD Cowen upgraded Eyepoint Pharmaceuticals (NASDAQ:EYPT) to a "strong-buy" rating, with an average target price of $30.00. Despite recent missed quarterly estimates and unprofitability, the company's focus on sustained-release ocular therapies and significant institutional ownership (~99%) highlight its potential. Shares traded up about 2.2% to $17.43 following the upgrade.
